Xelstrym (dextroamphetamine) NDC 68968-0210

NDC codes

FDA NDC Directory

Product NDC (as listed)68968-0210Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68968-0210Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68968-0210-3	68968021003	30 POUCH in 1 CARTON (68968-0210-3) / 1 PATCH, EXTENDED RELEASE in 1 POUCH (68968-0210-1)Marketed from May 15, 2023

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Xelstrym
Generic name (nonproprietary): dextroamphetamine
Active ingredients: Dextroamphetamine — 9 mg/1
Dosage form: Patch, Extended release
Route: Transdermal
Labeler: Noven Therapeutics, LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 215401
Marketing start: May 15, 2023
Listing expires: Dec 31, 2026
DEA schedule: CII
Other FDA classes: Central Nervous System Stimulation (Physiologic effect)
Identifiers: Product ID 68968-0210_11163145-d173-4320-aac9-92069f0cbf4aSPL ID 11163145-d173-4320-aac9-92069f0cbf4aSPL set ID 0862f02a-72a8-41cc-8845-57cf4974bb6fRxCUI 2624701, 2624708, 2624712, 2624715, 2624726, 2624729, 2624732, 2624735UNII TZ47U051FI
Pharmacologic class: Central Nervous System Stimulant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Transdermal products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468968021003 followed by a unit qualifier and the quantity

Package 68968-0210-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 23, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

XELSTRYM ® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see CLINICAL STUDIES (14) ] . Limitations of Use The use of XELSTRYM is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.5) , Use in Specific Populations (8.4) ]. XELSTRYM is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older ( 1 …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 215401

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 215401
Product	Strength	Form · route	Labeler	Product NDC
Xelstrymdextroamphetamine	Dextroamphetamine 4.5 mg/1	Patch, Extended releaseTransdermal	Noven Therapeutics, LLC	68968-0205
Xelstrymdextroamphetamine	Dextroamphetamine 13.5 mg/1	Patch, Extended releaseTransdermal	Noven Therapeutics, LLC	68968-0215
Xelstrymdextroamphetamine	Dextroamphetamine 18 mg/1	Patch, Extended releaseTransdermal	Noven Therapeutics, LLC	68968-0220